Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016
Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib Opportunity for first regulatory submissions in haematological malignancies in 2016
Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development
Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global,
AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical
One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients
BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.
Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.
